HuL001
- Generic Name
- HuL001
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- HuniLife Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04540770
- Locations
- 🇨🇳
Mackay Memorial Hospital, New Taipei City, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath